Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –

– Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes –

Read more at globenewswire.com